For research use only. Not for therapeutic Use.
BDZ-g is a potent, selective antagonist of AMPA receptor. BDZ-g has the potential for the research of various neurological disorders involving excessive activity of AMPA receptors[1].
| Catalog Number | I023130 |
| CAS Number | 732278-52-3 |
| Synonyms | 2-methyl-4-[(8R)-8-methyl-7-(5-methyl-1,3,4-thiadiazol-2-yl)-8,9-dihydro-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-5-yl]aniline |
| Molecular Formula | C21H21N5O2S |
| Purity | ≥95% |
| InChI | InChI=1S/C21H21N5O2S/c1-11-6-14(4-5-17(11)22)20-16-9-19-18(27-10-28-19)8-15(16)7-12(2)26(25-20)21-24-23-13(3)29-21/h4-6,8-9,12H,7,10,22H2,1-3H3/t12-/m1/s1 |
| InChIKey | DBDUGNPURSLMPS-GFCCVEGCSA-N |
| SMILES | CC1CC2=CC3=C(C=C2C(=NN1C4=NN=C(S4)C)C5=CC(=C(C=C5)N)C)OCO3 |
| Reference | [1]. Wang C, et al. Mechanism and site of inhibition of AMPA receptors: pairing a thiadiazole with a 2,3-benzodiazepine scaffold. ACS Chem Neurosci. 2014;5(2):138-147. |
